Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist

Annals of the Rheumatic Diseases

Volumn 58, Issue SUPPL. 1, 1999, Pages

  Bresnihan, Barry ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

CLINICAL TRIAL; DRUG EFFECT; DRUG SCREENING; HUMAN; IMMUNOPHARMACOLOGY; JOINT DEGENERATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0032703264     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.2008.i96     Document Type: Review

References (16)

1. Harris ED. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
2. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
3. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-147.
4. van den Berg WB. Lessons for joint destruction from animal models. Curr Opin Rheumatol 1997; 7:221-8.
5. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNFα, anti-IL-1α/β and IL-1Ra. Arthritis Rheum 1996;39:797-809.
6. Bakker AC, Josten LAB, Arntz OJ, et al. Gene therapy of murine collagen-induced arthritis ; Local expression of the human IL-1ra protein prevents onset. Arthritis Rheum 1997;40:893-900.
7. Drevlow BE, Lovis R, Haag MA, et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996;39: 257-65.
8. Campion GV, Lesback ME, Lookabaugh J, Gordon G, Catalano M and the IL-1ra Arthritis Study Group. Dose -range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092-101.
9. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1999; 41:2196-204.
10. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
11. Paulus HE, Egger MJ, Ward JR, Williams HJ and the Cooperative Systematic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on findings in patients treated with placebo. Arthritis Rheum 1990;33:447-84.
12. Nuki G, Rozman B, Pavelka K, Emery P, Lookabaugh J, Musikic P. Interleukin-1 receptor antagonist continues to demonstrate clinical improvement in rheumatoid arthritis. Arthritis Rheum 1997;40:S224.
13. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977;18:481-91.
14. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicentre, double-blind, dose ranging randomized and placebo controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiological progression and correlation of Genant and Larsen scoring methods. Arthritis Rheum (in press).
15. Bendele A, McAbee T, Sennello G, Fraizier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis. Arthritis Rheum 1999; 42:498-506.
16. Cunnane G, Cassidy N, Madigan A, Murphy E, FitzGerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist on the synovial membrane and joints of patients with rheumatoid arthritis. Arthritis Rheum 1998; 41;S138.